Sio Gene Therapies is pushing the boundaries of gene therapy to develop treatments for three debilitating neurodegenerative diseases, including clinical-stage product candidates in rare fatal pediatric disorders and adult Parkinson’s disease.

Ikena Oncology changed its name in late 2019 after a three-month deliberation process; the company previously went by Kyn Therapeutics. 

Craig Fraser, CEO of Windtree Therapeutics, became a U.S. Marine at age 17, learning to perform and lead under pressure in the field before eventually leading in the C-suite.

OncoSec Medical’s Tavo, a DNA-based interleukin-12 immunotherapy that is delivered to tumors via electroporation, is currently in Phase II trials

Scynexis announced it will commercially launch its Brexafemme (ibrexafungerp) therapy in the 3rd quarter of 2021 at a media event today. The company plans a full marketing rollout for its launch in the coming months.

OncoSec’s DNA-delivery system is designed to prompt the body to make more of its own IL-12. “The DNA essentially co-opts the cell’s function to cause it to make IL-12,” explained Daniel O’Connor, former CEO of OncoSec, in an interview.

A so-called multivalent vaccine might protect against all Covid-19 mutations and any future pathogen from the betacoronavirus family

Augmenta Bioworks and TFF Pharmaceuticals Inc have selected their first lead monoclonal antibody (mAb) for clinical development against COVID-19 as part of their collaborative alliance.